- Home
- REE vs MGNX Comparison
REE vs MGNX Comparison
Compare REE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- MGNX
- Stock Information
- Founded
- REE 2011
- MGNX 2000
- Country
- REE Israel
- MGNX United States
- Employees
- REE N/A
- MGNX N/A
- Industry
- REE Auto Manufacturing
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- MGNX Health Care
- Exchange
- REE Nasdaq
- MGNX Nasdaq
- Market Cap
- REE 77.3M
- MGNX 87.7M
- IPO Year
- REE N/A
- MGNX 2013
- Fundamental
- Price
- REE $0.61
- MGNX $1.33
- Analyst Decision
- REE Strong Buy
- MGNX Hold
- Analyst Count
- REE 2
- MGNX 9
- Target Price
- REE $11.75
- MGNX $5.33
- AVG Volume (30 Days)
- REE 238.9K
- MGNX 2.0M
- Earning Date
- REE 07-01-2025
- MGNX 08-05-2025
- Dividend Yield
- REE N/A
- MGNX N/A
- EPS Growth
- REE N/A
- MGNX N/A
- EPS
- REE N/A
- MGNX N/A
- Revenue
- REE $183,000.00
- MGNX $154,050,000.00
- Revenue This Year
- REE $7,039.34
- MGNX N/A
- Revenue Next Year
- REE $2,159.93
- MGNX N/A
- P/E Ratio
- REE N/A
- MGNX N/A
- Revenue Growth
- REE N/A
- MGNX 255.31
- 52 Week Low
- REE $0.61
- MGNX $0.99
- 52 Week High
- REE $11.72
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- REE 24.83
- MGNX 41.45
- Support Level
- REE $0.62
- MGNX $1.33
- Resistance Level
- REE $0.67
- MGNX $2.17
- Average True Range (ATR)
- REE 0.05
- MGNX 0.17
- MACD
- REE 0.07
- MGNX -0.02
- Stochastic Oscillator
- REE 3.10
- MGNX 2.38
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.